I have and I think they're misleading folks. Their Allovectin-7 trial just makes no sense to me and raises a lot of questions. Like why did the FDA give them an SPA for the primary endpoint of durable response rate(DRR) instead of PFS or OS? Why are they comparing it against DTIC/TMZ when TMZ isn't even approved for this indication?
Allovectin-7 has failed previous Phase 3 trials and their response has only been to just keep upping the dosage. Since their first Phase 3 trail, I think they've raised the dosing by a factor of 2000.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.